{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:21:11Z","timestamp":1783102871425,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["847583"],"award-info":[{"award-number":["847583"]}]},{"name":"Swedish Cancer Society","award":["CAN 2022\/1971"],"award-info":[{"award-number":["CAN 2022\/1971"]}]},{"name":"The Hjelm Family Foundation for Medical research"},{"name":"Mrs. Berta Kamprad\u2019s Cancer Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) has been the standard care for muscle-invasive bladder cancer (MIBC) for two decades. One third of NAC-treated patients achieve pathologic complete response (pT0N0), a proxy for improved survival after RC. Predicting response already at transurethral resection of bladder tumor (TUR-BT) would enable selective use of NAC, minimizing exposure to ineffective therapy. We aimed to identify tumor mRNAs associated with response across multiple transcriptomic studies, prioritizing subsequent biomarkers for validation. Three NAC-treated cohort with tumor transcriptomic profiles were included. Differential mRNA-expression analysis and subtype classification according to the Lund Taxonomy were performed. Within each cohort and subtype, genes were ranked by differential expression, and integrated into a meta rank-score. Survival associations of top genes in the NAC-cohorts were used to select candidate biomarkers for protein validation. Proliferation\/late cell-cycle gene predicted response in Urothelial-like subtype and cytotoxic T- and NK-cell-related genes predicted response in Basal\/Squamous tumors. These findings were validated by immunostainings for CCNB1 and NKG7, respectively. This integrative framework suggests a complex picture in which two NAC-predictive signals identify responders in a subtype dependent manner. The framework can be updated as new datasets become available, providing dynamic exploration of NAC-predictive biomarkers in MIBC.<\/jats:p>","DOI":"10.1038\/s41698-026-01588-7","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:34:13Z","timestamp":1783100053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner"],"prefix":"10.1038","volume":"10","author":[{"given":"Aymeric","family":"Zadoroznyj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Adam","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Tangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfrid","family":"Sj\u00f6dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1588_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","year":"2005","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202\u2013205 (2005).","journal-title":"Eur. Urol."},{"key":"1588_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"JA Witjes","year":"2024","unstructured":"Witjes, J. A. et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331 (2024).","journal-title":"Eur. Urol."},{"key":"1588_CR3","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773\u20131786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1588_CR4","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","volume":"394","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke, C. et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N. Engl. J. Med. 394, 1257\u20131269 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1588_CR5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","volume":"61","author":"R Rosenblatt","year":"2012","unstructured":"Rosenblatt, R. et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur. Urol. 61, 1229\u20131238 (2012).","journal-title":"Eur. Urol."},{"key":"1588_CR6","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.juro.2013.10.142","volume":"191","author":"HJ Lavery","year":"2014","unstructured":"Lavery, H. J., Stensland, K. D., Niegisch, G., Albers, P. & Droller, M. J. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. J. Urol. 191, 898\u2013906 (2014).","journal-title":"J. Urol."},{"key":"1588_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","volume":"65","author":"F Petrelli","year":"2014","unstructured":"Petrelli, F. et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur. Urol. 65, 350\u2013357 (2014).","journal-title":"Eur. Urol."},{"key":"1588_CR8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eururo.2017.05.016","volume":"72","author":"B Bhindi","year":"2017","unstructured":"Bhindi, B. et al. Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis. Eur. Urol. 72, 660\u2013664 (2017).","journal-title":"Eur. Urol."},{"key":"1588_CR9","doi-asserted-by":"crossref","unstructured":"Reesink, D. J., et al. Survival in responders and nonresponders of neoadjuvant and induction chemotherapy in invasive urothelial carcinoma of the urinary bladder: a clinical and pathological stage-matched analysis. Clin. Genitourin. Cancer 23, 102319 (2025).","DOI":"10.1016\/j.clgc.2025.102319"},{"key":"1588_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18640-0","volume":"11","author":"A Taber","year":"2020","unstructured":"Taber, A. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11, 4858 (2020).","journal-title":"Nat. Commun."},{"key":"1588_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","volume":"81","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl, G. et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur. Urol. 81, 523\u2013532 (2022).","journal-title":"Eur. Urol."},{"key":"1588_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.annonc.2024.09.008","volume":"36","author":"CS Groeneveld","year":"2025","unstructured":"Groeneveld, C. S. et al. Basal\/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial. Ann. Oncol. 36, 89\u201398 (2025).","journal-title":"Ann. Oncol."},{"key":"1588_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186688","volume":"135","author":"J B\u00f6rcs\u00f6k","year":"2025","unstructured":"B\u00f6rcs\u00f6k, J. et al. Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer. J. Clin. Invest. 135, e186688 (2025).","journal-title":"J. Clin. Invest."},{"key":"1588_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3735","volume":"13","author":"T Vollmer","year":"2021","unstructured":"Vollmer, T. et al. The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. Sci. Transl. Med. 13, eabb3735 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1588_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/cancers13030494","volume":"13","author":"EF Nassif","year":"2021","unstructured":"Nassif, E. F. et al. The immunoscore in localized urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathologic responses and overall survival. Cancers 13, 494 (2021).","journal-title":"Cancers"},{"key":"1588_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"1588_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100382","volume":"2","author":"H Mi","year":"2021","unstructured":"Mi, H. et al. Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. Cell Rep. Med. 2, 100382 (2021).","journal-title":"Cell Rep. Med."},{"key":"1588_CR18","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu, D. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2, 1094\u20131096 (2016).","journal-title":"JAMA Oncol."},{"key":"1588_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2022.07.023","volume":"83","author":"A Gil-Jimenez","year":"2023","unstructured":"Gil-Jimenez, A. et al. Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer. Eur. Urol. 83, 313\u2013317 (2023).","journal-title":"Eur. Urol."},{"key":"1588_CR20","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/j.febslet.2008.02.040","volume":"582","author":"S Khurana","year":"2008","unstructured":"Khurana, S. & George, S. P. Regulation of cell structure and function by actin-binding proteins: villin\u2019s perspective. FEBS Lett. 582, 2128\u20132139 (2008).","journal-title":"FEBS Lett."},{"key":"1588_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/PAS.0000000000000142","volume":"38","author":"A Fleischmann","year":"2014","unstructured":"Fleischmann, A., Thalmann, G. N., Perren, A. & Seiler, R. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival. Am. J. Surg. Pathol. 38, 325\u2013332 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"1588_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.eururo.2023.11.008","volume":"85","author":"W Beckabir","year":"2024","unstructured":"Beckabir, W. et al. Spatial relationships in the tumor microenvironment demonstrate association with pathologic response to neoadjuvant chemoimmunotherapy in muscle-invasive bladder cancer. Eur. Urol. 85, 242\u2013253 (2024).","journal-title":"Eur. Urol."},{"key":"1588_CR23","doi-asserted-by":"publisher","first-page":"e1134412","DOI":"10.1080\/2162402X.2015.1134412","volume":"5","author":"AS Baras","year":"2016","unstructured":"Baras, A. S. et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology 5, e1134412 (2016).","journal-title":"Oncoimmunology"},{"key":"1588_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101393","volume":"5","author":"MD Galsky","year":"2024","unstructured":"Galsky, M. D. et al. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. Cell Rep. Med. 5, 101393 (2024). Feb 20.","journal-title":"Cell Rep. Med."},{"key":"1588_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.urolonc.2019.04.010","volume":"37","author":"P Kollberg","year":"2019","unstructured":"Kollberg, P., Chebil, G., Eriksson, P., Sj\u00f6dahl, G. & Liedberg, F. Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival. Urol. Oncol. 37, 791\u2013799 (2019).","journal-title":"Urol. Oncol."},{"key":"1588_CR26","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1200\/JCO.22.02762","volume":"41","author":"JP Stein","year":"2023","unstructured":"Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 41, 3772\u20133781 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1588_CR27","doi-asserted-by":"publisher","first-page":"34.e17","DOI":"10.1016\/j.urolonc.2016.08.005","volume":"35","author":"A Brant","year":"2017","unstructured":"Brant, A. et al. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: is therapeutic effect owing to chemotherapy or TURBT? Urol. Oncol. 35, 34.e17\u201334.e25 (2017).","journal-title":"Urol. Oncol."},{"key":"1588_CR28","doi-asserted-by":"publisher","first-page":"62.e1","DOI":"10.1016\/j.urolonc.2024.09.015","volume":"43","author":"M de Angelis","year":"2025","unstructured":"de Angelis, M. et al. Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma. Urol. Oncol. 43, 62.e1\u201362.e6 (2025).","journal-title":"Urol. Oncol."},{"key":"1588_CR29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"1588_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/BLC-220124","volume":"9","author":"M H\u00f6glund","year":"2023","unstructured":"H\u00f6glund, M. What is a bladder cancer molecular subtype? Bladder Cancer 9, 293\u2013298 (2023).","journal-title":"Bladder Cancer"},{"key":"1588_CR31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jmoldx.2024.08.005","volume":"26","author":"EA Cotillas","year":"2024","unstructured":"Cotillas, E. A. et al. A versatile and upgraded version of the LundTax classification algorithm applied to independent cohorts. J. Mol. Diagn. 26, 1081\u20131101 (2024).","journal-title":"J. Mol. Diagn."},{"key":"1588_CR32","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.18632\/oncotarget.28302","volume":"13","author":"N Murphy","year":"2022","unstructured":"Murphy, N. et al. Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer. Oncotarget 13, 1188\u20131200 (2022).","journal-title":"Oncotarget"},{"key":"1588_CR33","doi-asserted-by":"crossref","unstructured":"Conroy, S. et al. Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction. Commun. Med. (2026).","DOI":"10.1038\/s43856-026-01596-5"},{"key":"1588_CR34","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","volume":"27","author":"TW Flaig","year":"2021","unstructured":"Flaig, T. W. et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin. Cancer Res. 27, 2435\u20132441 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1588_CR35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/1078-0432.CCR-23-0602","volume":"30","author":"SP Lerner","year":"2024","unstructured":"Lerner, S. P. et al. Association of molecular subtypes with pathologic response, PFS, and OS in a phase II study of COXEN with neoadjuvant chemotherapy for muscle-invasive bladder cancer. Clin. Cancer Res 30, 444\u2013449 (2024).","journal-title":"Clin. Cancer Res"},{"key":"1588_CR36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544\u2013554 (2017).","journal-title":"Eur. Urol."},{"key":"1588_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sj\u00f6dahl","year":"2017","unstructured":"Sj\u00f6dahl, G., Eriksson, P., Liedberg, F. & H\u00f6glund, M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242, 113\u2013125 (2017).","journal-title":"J. Pathol."},{"key":"1588_CR38","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","volume":"36","author":"SX Ge","year":"2020","unstructured":"Ge, S. X., Jung, D. & Yao, R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics 36, 2628\u20132629 (2020).","journal-title":"Bioinformatics"},{"key":"1588_CR39","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1588_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1021\/acs.jproteome.8b00702","volume":"18","author":"NT Doncheva","year":"2019","unstructured":"Doncheva, N. T., Morris, J. H., Gorodkin, J. & Jensen, L. J. Cytoscape StringApp: network analysis and visualization of proteomics data. J. Proteome Res. 18, 623\u2013632 (2019).","journal-title":"J. Proteome Res."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01588-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:56:19Z","timestamp":1783101379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01588-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01588-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.C.B. and R.S. share a patent with Veracyte which played no role or is linked to the work presented here (Inventors Elai Davicioni, Hussam Al-Deen Ashab, Nicholas Erho, Peter Black; EP 3 571 322 B8 date of publication and mention of the grant patent 07.06.2023). The other authors do not have a competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}